Search

47:03","modified_gmt":"2017-07-17T09:47:03","slug":"human-antibodies-developed-for-treatment-of-lupus-and-anthrax","status":"publish","type":"post","link":"https://www2.mrc-lmb.cam.ac.uk/ ... n. The drug candidatesu2014belimumab (BENLYSTATM, formerly

approved-for-treatment-of-lupus/","title":{"rendered":"Human antibody approved for treatment of lupus"},"content":{"rendered":". Systemic lupus erythematosus is a chronic, life-threatening inflammatory autoimmune disease that can cause debilitating

11 Mar 2011: Search this website. Human antibody approved for treatment of lupus. Human antibody approved for treatment of lupus. ... Food and Drug Administration. It is the first new drug treatment for lupus in 50 years, and the second human therapeutic antibody,

Human antibody approved for treatment of lupus. ... Published on. 11 March, 2011. Systemic lupus erythematosus is a chronic, life-threatening inflammatory autoimmune disease that can cause debilitating fatigue, painful and swollen joints, fever, skin rash

{"id":4193,"date":"2013-01-07T13:50:34","date_gmt":"2013-01-07T13:50:34","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/research/technology-transfer/history-of-technology-transfer/"},"modified":"2023-07-21T12:49:41","modified_gmt":"2023-

23 Feb 2024: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. ... Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

23 Feb 2024: Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipidsyndrome: A systematic review.

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. ... An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in

31 Jul 2009: The drug candidates—belimumab (BENLYSTATM, formerly LumphoStat-B), developed by Human Genome Sciences with GlaxoSmithKine as a treatment for systemic lupus erythematosus and raxibacumab (ABthrax), developed by Human Genome Sciences as ... If approved,

21 Jul 2023: This antibody, for treatment of rheumatoid arthritis, proved a blockbuster drug with total sales of more than $10 billion by the end of 2009. ... Other antibodies followed, including BENLYSTA, which promises to be the first new drug treatment for